March 01, 2011 -- Deinove (Paris : ALDEI) (Alternext Paris: ALDEI), the world's leading specialist in Deinococcus bacteria for biofuels, green chemistry and antibiotics, has been selected to present at CleanEquity Monaco 2011, the foremost event for next generation clean and green technology. The conference will take place on March 3rd and 4th at the Sporting d'Hiver in Monaco.
Deinove was included by expert selection, as one of the world's most inspiring cleantech companies, to present to industry-specific, senior financial and strategic investors, policy makers, legislators, end users and media.
Innovator Capital, the London specialist investment bank, hosts the annual invitation-only event. CleanEquity Monaco's regional host is the Monaco Chamber of Economic Development.
Other local partners include Prince Albert II of Monaco's Foundation, the Monte Carlo SBM, and the Stelios Philanthropic Foundation. Collaborators for the 2011 event include The United Nations (UNEP Fi), Covington and Burling, PR Newswire, The Carbon War Room, Invest Securities, 21 Ventures and Biocode Incubation.
?Deinove is pleased to present its recent development and corporate strategy at the world-renowned CleanEquity Monaco 2011. This would be a great opportunity for us to present our breakthrough industrial microbial processes for the production of 2nd-generation biofuels, chemical commodities and compounds of industrial interest using Deinococcus and other radio-resistant bacteria?, emphasized Deinove CEO Jacques Biton.
The greentech company Deinove (Alternext Paris: ALDEI) is dedicated to the development and commercial exploitation of innovative technological processes for the production of biofuels and other compounds of industrial or pharmaceutical interest, by exploiting the deinococci's exceptional natural properties. Deinove successfully floated on the Alternext stock market in April 2010. The company intends to leverage its proprietary bacterial strains, technologies and processes by outlicensing to industrial partners. Deinove has partnered with leading sugar, ethanol and starch company TEREOS in order to develop the Deinol project, which aims at producing cellulosic ethanol in existing industrial facilities.
Deinove currently has 23 staff and operates several collaborative R&D programmes with the CNRS (Montpellier and Marseilles), the University of Paris V, INSA Toulouse and the VTT in Finland. It was incorporated in late 2006 under the joint impetus of Philippe Pouletty MD (Managing Partner at the private equity firm Truffle Capital) and Professor Miroslav Radman (Professor of Cell Biology at Paris-Descartes University, a member of the French Academy of Science and winner of the 2003 INSERM Medical Research Prize). Professor Radman elucidated the genetic mechanism behind the extraordinary natural properties of the bacterium Deinococcus (biodiversity and robustness) on which Deinove's innovation strategy is based. The company's headquarters are in Paris and it operates a lab in Montpellier (Cap Alpha technopark), southern France.
For more information, visit www.deinove.com.
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Deinove ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavourable developments in connection with these and other risks and uncertainties described, in particular, in Chapter 4 of the Company's prospectus prepared in connection with its IPO and on which the French Autorité des Marches Financiers (?AMF?) granted its visa n°. 10-014 on March 25 2010, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
Updates are available on the company's website http://www.deinove.com
Help protect the environment: if you wish to stay up to date with our corporate news and receive our newsletters in an electronic format, please send your contact details (including your e-mail address and phone number) to firstname.lastname@example.org or subscribe to our RSS Feed on www.deinove.com.
DEINOVE SA – 22, rue Léon Jouhaux, F-75010 Paris, France – Tel.: + 33 (0)1 42 03 27 37 – Fax: +33 (0)1 47 23 54 03 email@example.com – www.deinove.com
Tel.: +33 142 68 86 43 / +33 664 18 99 59
Angelita de Francisco
Operations and Strategic Marketing Director
Tel.: +33 142 03 27 32 / + 33 607 15 28 87